Previous 10 | Next 10 |
Follows approval by several other major German providers Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders a...
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will present at ...
Myomo (MYO) surged 27% in premarket trade after it inked a joint venture agreement with Beijing Ryzur Medical Investment for manufacturing and selling the company's current and future products in greater China, including Hong Kong, Macau and Taiwan.Majo...
Edesa Biotech (EDSA) +97% on regulatory nod for sub set of phase2/3 EB05 COVID-19 study.Koss Corporation (KOSS) +84%.Phunware (PHUN) +65%.Vertex Energy (VTNR) +52%.Myomo (MYO) +33% on JV to manufacture and sell the company’s products in China.AIkido Pharma (AIKI) +2...
Joint Venture intends to enter into technology agreement with upfront license fee and minimum purchase requirements Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased function...
Myomo ([[MYO]] +8.5%) reports preliminary 4Q20 is expected to be between $3.2M and $3.7M vs. $2.16M consensus; represents an increase of 110% to 143% year-over-year.Expects revenue FY20 to be between $7M and $7.5M vs. $5.95M consensus, increase of 84% to 97% year-over-year.Company had cash an...
Fourth Quarter 2020 Revenue Expected to More than Double Compared With Fourth Quarter 2019 Quarterly cash utilization is the lowest since IPO in 2017 Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robot...
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, the Company...
Gainers: AnPac Bio-Medical Science (ANPC) +110%, Cocrystal Pharma (COCP) +56%, Renalytix AI (RNLX) +31%, Precigen (PGEN) +13%, Chiasma (CHMA) +11%.Losers: Hepion Pharmaceuticals (HEPA) -29%, Medigus (MDGS) -12%, Retractable Technologies (...
Presentation Times and Weblinks Released for Over 60 Presenting Companies Today: Thursday, November 19, 2020 NEW YORK, NY / ACCESSWIRE / November 19, 2020 / Sidoti & Company, LLC proudly releases the presentation schedule, with weblink click-throughs, for today's Virtual Microc...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 17:00:05 ET Scott Henry from Industrial Alliance Securities issued a price target of $5.75 for MYO on 2024-07-10 15:33:00. The adjusted price target was set to $5.75. At the time of the announcement, MYO was trading at $4.97. The overall price target consensus...
2024-07-10 16:15:02 ET Alliance Global Partners analyst issues BUY recommendation for MYO on July 10, 2024 03:33PM ET. The previous analyst recommendation was Buy. MYO was trading at $4.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-07-09 10:30:11 ET Lake Street analyst issues BUY recommendation for MYO on July 9, 2024 08:45AM ET. The previous analyst recommendation was Buy. MYO was trading at $4.07 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...